Show simple item record

dc.contributor.authorPatel, M. R.en
dc.contributor.authorAhearne, M.en
dc.contributor.authorLinton, Kim Men
dc.contributor.authorFox, C.en
dc.contributor.authorLewis, D. J.en
dc.contributor.authorHiggins, M.en
dc.contributor.authorSchwartz, B. E.en
dc.contributor.authorBeer, P. A.en
dc.contributor.authorTees, M. T.en
dc.date.accessioned2023-10-25T08:48:38Z
dc.date.available2023-10-25T08:48:38Z
dc.date.issued2023en
dc.identifier.citationPatel MR, Ahearne M, Linton K, Fox C, Lewis DJ, Higgins M, et al. A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005456.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.TPS7591en
dc.identifier.urihttp://hdl.handle.net/10541/626661
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS7591en
dc.titleA phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentFlorida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FLen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record